DataString Consulting Company Logo
DataString Consulting Company Logo
Afatinib Tablets Market
Home»Top Market Reports»Afatinib Tablets Market

Afatinib Tablets Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802095, Published - March 2025

Segmented in Therapeutic Application (Lung Cancer, Head & Neck Cancer, Breast Cancer, Others), Formulation (20mg, 30mg, 40mg, 50mg), User Age Group, Distribution Channel, Treatment Protocol and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Afatinib Tablets Market Outlook

The market, for Afatinib tablets was estimated at $980.0 million in 2024; and it is anticipated to increase to $2.4 billion by 2030 with projections indicating a growth to around $5.2 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 16.3% over the forecast period. The impressive growth of the Afatinib tablets market is driven by important factors which include the rising number of cancer cases worldwide with a particular focus on lung cancer where Afatinib has proven to be an effective treatment choice. They also continue to play a role due to advancements in targeted therapies and the notable increase in healthcare spending globally along with the continuous progress, in pharmacological research and innovations. The increasing popularity of Afatinib tablets in the healthcare industry is largely due to partnerships formed by major pharmaceutical companies and the approval of regulations, for generic versions of the drug being introduced to the market.


Afatinib tablets have significantly transformed the landscape of lung cancer treatment for individuals with small cell lung cancer (NSCL). These medications work by blocking the growth of cancer cells through targeting proteins on their surface and are known for their effectiveness, in slowing the advancement of metastatic NSCL and halting tumor growth.


Market Size Forecast & Key Insights

2019
$980M2024
2029
$4.4B2034

Absolute Growth Opportunity = $3.5B

The Afatinib Tablets market is projected to grow from $980.0 million in 2024 to $4.44 billion in 2034. This represents a CAGR of 16.3%, reflecting rising demand across Treatment of Non-Small Cell Lung Cancer, Management of Metastatic Breast Cancer and Squamous Cell Carcinoma Treatment.

The Afatinib Tablets market is set to add $3.5 billion between 2024 and 2034, with manufacturer targeting 30mg & 40mg Formulation projected to gain a larger market share.

With Advancements in targeted cancer therapies, and Increasing global incidence of lung cancer, Afatinib Tablets market to expand 353% between 2024 and 2034.

Opportunities in the Afatinib Tablets Market

Penetration in Untapped Markets

The global need for lung cancer drugs like afatinib tablets is on the rise as more people are becoming aware of cancer treatments and investing more in healthcare services in developing countries where there is potential for growth, in this market.

Technological Innovations in Medication Delivery and Strategic Collaborations and Partnership Expansions

The direction of afatinib tablets in the future may see impact from advancements in medication delivery technology, like oral dispersion tablets and effervescent tablets that could boost the efficacy of afatinib through better absorption rates and consequently speed up its adoption rate.

Establishing partnerships with pharmaceutical companies opens up fresh possibilities, for afatinib tablets advancement. By engaging in these alliances manufacturers stand to benefit from sharing strategies, unlocking novel research and development techniques and resources that may enhance the manufacturing process and boost the effectiveness of afatinib tablets further.

Growth Opportunities in North America and Europe

Europe Outlook

The market for afatinib tablets in Europe is experiencing expansion because of the rising occurrence of EGFR mutation positive NSCLC cases. The quick approval of drugs by the European Medicines Agency plays a role, in enhancing the availability and sales of afatinib tablets. Stringent manufacturing standards and pharmaceutical regulations guarantee the production of top notch products that help build trust among customers. However the European market is quite competitive with companies from Europe and around the world like AstraZeneca and Roche vying to increase their market presence Moreover patent expiration of important medications and growing generics competition pose potential obstacles for the industry, in this region.

North America Outlook

North America plays a role in the market for afatinib tablets due to its high prevalence of lung cancer and well developed healthcare system that emphasizes effective cancer treatments like afatinib tablets demanded by patients in need of oncology care. Additionally the region benefits from a rise in research and development efforts and the strong presence of major industry players such as Boehringer Ingelheim that contribute significantly to the growth of this sector, in North America. Additionally government efforts to guarantee cost cancer therapies and thorough public awareness drives are playing a substantial role in driving the vibrant development of the market for afatinib tablets, in North America. Nonetheless the region is encountering competition from formidable rivals manufacturing EGFR inhibitors across the globe.

North America Outlook

North America plays a role in the market for afatinib tablets due to its high prevalence of lung cancer and well developed healthcare system that emphasizes effective cancer treatments like afatinib tablets demanded by patients in need of oncology care. Additionally the region benefits from a rise in research and development efforts and the strong presence of major industry players such as Boehringer Ingelheim that contribute significantly to the growth of this sector, in North America. Additionally government efforts to guarantee cost cancer therapies and thorough public awareness drives are playing a substantial role in driving the vibrant development of the market for afatinib tablets, in North America. Nonetheless the region is encountering competition from formidable rivals manufacturing EGFR inhibitors across the globe.

Europe Outlook

The market for afatinib tablets in Europe is experiencing expansion because of the rising occurrence of EGFR mutation positive NSCLC cases. The quick approval of drugs by the European Medicines Agency plays a role, in enhancing the availability and sales of afatinib tablets. Stringent manufacturing standards and pharmaceutical regulations guarantee the production of top notch products that help build trust among customers. However the European market is quite competitive with companies from Europe and around the world like AstraZeneca and Roche vying to increase their market presence Moreover patent expiration of important medications and growing generics competition pose potential obstacles for the industry, in this region.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, Japan, United Kingdom, India are expected to grow at 15.6% to 22.8% CAGR

2

Emerging Markets : Brazil, South Africa, Turkey are expected to grow at 12.2% to 17.0% CAGR

Market Analysis Chart

The market trends for afatinib tablets are influenced by factors that serve as both catalysts and inhibitors of growth. One significant driving force is the rising incidence of lung cancer which fuels the demand for treatments like afatinib tablets in targeted therapy interventions. This surge in demand is a testament to the tablets’ efficacy, in combating the spread of cancer cells and highlights their importance in today’s field.

Recent Developments and Technological Advancement

December 2024

Merck, a pharmaceutical company has just finished the third phase of clinical trials, for a new afatinib tablet version that aims to decrease side effects.

October 2024

Sanofi has ventured into the market for afatinib tablets by forming a partnership, with Glaxosmithkline Pharmaceuticals to enhance its range of oncology products.

August 2024

In response to the increasing need, for lung cancer treatment medication afatinib tablets. Pfizer Inc. has allocated $100 million towards enhancing its manufacturing processes.

The field of pharmaceuticals has seen advancements in recent times with afatinib tablets standing out as a prime example of innovation in the sector. Given the increasing need, for this effective treatment option the market has significantly grown to meet the demands of patients seeking reliable anti cancer remedies.

Impact of Industry Transitions on the Afatinib Tablets Market

As a core segment of the Pharmaceutical industry, the Afatinib Tablets market develops in line with broader industry shifts. Over recent years, transitions such as Precision Oncology Advancements and Growing Emphasis on Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Afatinib Tablets market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Precision Oncology Advancements:

The progress in precision oncology has had an impact on the importance and effectiveness of afatinib tablets. s This development involves using data to tailor cancer treatments specifically to each patients needs. s This approach has led to improvements in treatment outcomes and a reduction in side effects. s In this context s afatinib tablets, s renowned for their success in treating small cell lung cancer with specific mutations in the epidermal growth factor receptor s have garnered increased attention. s The shift towards medicine has not only influenced clinical decisions and treatment strategies but also shifted the focus of research, within the pharmaceutical sector.

2

Growing Emphasis on Personalized Medicine:

The rising focus on customizing care in the healthcare field has made afatinib tablets increasingly important. These tablets play a role in personalized medicine by pinpoint the best treatment approach based on an individuals genetic profile and disease specifics. With the growing interest in medicine because they can target specific cancer related genetic mutations effectively the potential of afatinib tablets is, on the rise.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Afatinib Tablets market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Advancements in Targeted Cancer Therapies, and Expansion in Healthcare Infrastructure in Developing Countries

The changing field of medicine has also expanded the range of cancer therapies available today and has also seen a notable rise in the utilization of afatinib tablets for treatment purposes. Afatinib tablets are also well regarded for their ability to selectively and permanently block the ErbB family proteins and are also commonly prescribed for treating small cell lung cancer cases with particular genetic mutations. This personalized approach to medication offers a targeted and effective treatment plan tailored to individual patients needs and health outcomes – consequently fueling the growing demand for afatinib tablets, in the market.
Emerging nations are also experiencing advancements in their healthcare systems as they expand their infrastructure to cater to the needs of their populations better. This development is also set to enhance the availability of medical solutions like afatinib tablets for treating non small cell lung cancer. The surge in healthcare infrastructure is also anticipated to drive up the demand for afatinib tablets in these regions and shape a favorable path, for the market ahead.
Every year sees a concerning rise in the prevalence of lung cancer which calls for immediate attention towards developing trustworthy and efficient treatments for the disease. The effectiveness of Afatinib tablets as a tyrosine kinase inhibitor has also been evident in various clinical studies showcasing promising outcomes that hint at a considerable growth potential, in the market ahead.

Restraint: High Cost of Treatment

The expensive nature of afatinib tablets poses a challenge in the market scenario at present time; these tablets are priced at a premium level which renders them inaccessible to the common patient population; particularly in regions that are underdeveloped or still in the process of development. This hefty price hurdle not only limits the global market growth but also leads to a decline in projected sales figures. The high price point primarily stems from the research and development expenditures involved throughout the production phase along, with costly raw materials and manufacturing procedures. Affordability plays a role here as it greatly affects the demand curve and overall dynamics of the afatinib tablets market.

Challenge: Regulatory Hurdles

Another substantial obstacle clogging the growth pipeline of this market are the stringent regulatory guidelines and approval processes. In order to ensure safety and efficacy, health regulatory authorities like FDA and EMA have established rigorous procedures for drug approval. These bodies demand a thorough documentation, including extensive clinical trial data, which may often result in prolonged time-to-market for novel drugs.

Supply Chain Landscape

Raw Material Suppliers

Aceto Corporation

Eastman Chemical Company

API Production

Boehringer Ingelheim

Novartis AG

Tablet Formulation
Pfizer Inc / AstraZeneca
Distribution & Retail
Walgreens / CVS Health / Rite Aid
Raw Material Suppliers

Aceto Corporation

Eastman Chemical Company

API Production

Boehringer Ingelheim

Novartis AG

Tablet Formulation

Pfizer Inc

AstraZeneca

Distribution & Retail

Walgreens

CVS Health

Rite Aid

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Non-Small Cell Lung Cancer (NSCLC)
Pharmaceuticals
Boehringer Ingelheim
Focus on scientifically-infused development, enhanced patient accessibility, and consistent quality assurance
Breast Cancer Treatment
Healthcare
Novartis
Development of personalized healthcare approaches, enhancing patient outcomes through targeted medicine and robust clinical trials
Head and Neck Cancer Treatment
Biotechnology
AstraZeneca
Investment in innovative scientific techniques, capability expansion through strategic partnerships, and commitment to patient-centered solutions
Pancreatic Cancer Management
Medical
GlaxoSmithKline
Leveraging advanced technologies for diagnosis and treatment, research collaboration for drug enhancement, and commitment to global health improvement

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Afatinib Tablets market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Afatinib Tablets in Squamous Cell Carcinoma Treatment and Management of Metastatic Breast Cancer and Treatment of Non-Small Cell Lung Cancer

Squamous Cell Carcinoma Treatment and Management of Metastatic Breast Cancer

Afatinib tablets have found another use in treating squamous cell carcinoma of the lung when standard chemotherapy has not only been effective for patients in need of alternative options. The medication has demonstrated effectiveness in inhibiting the progression and metastasis of cancer cells. Offers hope to individuals facing limited treatment choices. AstraZeneca incorporates afatinib into their treatment protocols to take advantage of its properties and uphold their prominent position, in the pharmaceutical market.

Afatinib tablets are used to treat breast cancer by focusing and obstruct the HER and EGFR proteins that are abundant, in specific forms of breast cancer thus hindering the proliferation of cancerous cells.

Treatment of Non-Small Cell Lung Cancer

Afatinib pills are mainly prescribed for treating Non Small Cell Lung Cancer . They belong to a group of drugs known as tyrosine kinase inhibitors that function by hindering the growth of cells in the bodys system when the illness has progressed to other region's or hasnt shown improvement with previous treatments. This particular medicine is typically recommended in cases where other therapies have been ineffective. The manufacturer of these tablets is Boehringer Ingelheim. They have achieved considerable success, in the market thanks to afatinibs unique benefits in managing NSCL.

Afatinib Tablets vs. Substitutes:
Performance and Positioning Analysis

Afatinib tablets, as opposed to alternatives like gefitinib or erlotinib, demonstrate proven efficacy in managing advanced lung cancer. Their unique market position arises from nuanced targeting of EGFR mutations, suggesting potential for significant market expansion. These Alternatives specially Erlotinib Hcl Tablets has experienced a rapid growth as detailed in our latest report.

Afatinib Tablets
  • Gefitinib tablets /
  • Erlotinib Hcl Tablets /
  • Osimertinib tablets
    Effective treatment for non-small cell lung cancer, targets the source of tumor growth
    Risk of severe diarrhea, potential for skin and
    Effective in blocking multiple pathways involved in cancer growth, diversity of choices based on patient-specific needs
    Stringent side effects, high

Afatinib Tablets vs. Substitutes:
Performance and Positioning Analysis

Afatinib Tablets

  • Effective treatment for non-small cell lung cancer, targets the source of tumor growth
  • Risk of severe diarrhea, potential for skin and

Gefitinib tablets / Erlotinib Hcl Tablets / Osimertinib tablets

  • Effective in blocking multiple pathways involved in cancer growth, diversity of choices based on patient-specific needs
  • Stringent side effects, high

Afatinib tablets, as opposed to alternatives like gefitinib or erlotinib, demonstrate proven efficacy in managing advanced lung cancer. Their unique market position arises from nuanced targeting of EGFR mutations, suggesting potential for significant market expansion. These Alternatives specially Erlotinib Hcl Tablets has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Afatinib Tablets market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Afatinib Tablets across Lung Cancer, Head & Neck Cancer, and Breast Cancer Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Boehringer Ingelheim, Pfizer Inc, and Roche Holding AG by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, API Production, and Tablet Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Afatinib Tablets segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Aceto Corporation, Eastman Chemical Company), API Production (Boehringer Ingelheim, Novartis AG), and Tablet Formulation. Our parallel substitute analysis examines Gefitinib tablets, Erlotinib Hcl Tablets, and Osimertinib tablets, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Boehringer Ingelheim, Pfizer Inc, and Roche Holding AG, analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Afatinib Tablets market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Afatinib Tablets Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.14 billion
Revenue Forecast in 2034USD 4.44 billion
Growth RateCAGR of 16.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024980 million
Growth OpportunityUSD 3.5 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024980 million USD
Market Size 20271.54 billion USD
Market Size 20292.09 billion USD
Market Size 20302.42 billion USD
Market Size 20344.44 billion USD
Market Size 20355.16 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredTherapeutic Application, Formulation, User Age Group, Distribution Channel, Treatment Protocol
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBoehringer Ingelheim, Pfizer Inc, Roche Holding AG, Novartis AG, AstraZeneca Plc, Teva Pharmaceuticals, Dr. Reddy's Laboratories Ltd, Glenmark Pharmaceuticals, Piramal Enterprises, Sun Pharmaceuticals, Cipla Inc and Biocon Ltd.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Afatinib Tablets Market Size, Opportunities & Strategic Insights, by Therapeutic Application

4.1Lung Cancer
4.2Head & Neck Cancer
4.3Breast Cancer
4.4Others
Chapter 5

Afatinib Tablets Market Size, Opportunities & Strategic Insights, by Formulation

5.120mg
5.230mg
5.340mg
5.450mg
Chapter 6

Afatinib Tablets Market Size, Opportunities & Strategic Insights, by User Age Group

6.1Pediatric
6.2Adult
6.3Senior Adult
Chapter 7

Afatinib Tablets Market Size, Opportunities & Strategic Insights, by Distribution Channel

7.1Hospital Pharmacies
7.2Retail Pharmacies
7.3Online Pharmacies
Chapter 8

Afatinib Tablets Market Size, Opportunities & Strategic Insights, by Treatment Protocol

8.1First Line Treatment
8.2Second Line Treatment
8.3Advanced Therapy
Chapter 9

Afatinib Tablets Market, by Region

9.1North America Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Afatinib Tablets Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Boehringer Ingelheim
10.2.2Pfizer Inc
10.2.3Roche Holding AG
10.2.4Novartis AG
10.2.5AstraZeneca Plc
10.2.6Teva Pharmaceuticals
10.2.7Dr. Reddy's Laboratories Ltd
10.2.8Glenmark Pharmaceuticals
10.2.9Piramal Enterprises
10.2.10Sun Pharmaceuticals
10.2.11Cipla Inc
10.2.12Biocon Ltd.